- PLN36.40m
- PLN51.87m
- PLN60.90m
Brief: BioMaxima Signs 1 Mln Zloty Deal Regarding Analyzer For Monitoring Cell Cultures
Brief: Biomaxima Starts Buyback Of Up To 432,000 Shares At Max. Price Of 33 Zlotys/Shr
Brief: Biomaxima Says Shareholders Acting In Agreement To Vote For Buyback
Brief: BioMaxima Signs Additional 0.9 Mln Zloty Deal With Polish Pharmaceutical Company
Brief: Biomaxima Management Recommends 2021 Dividend At 0.45 Zloty/Shr
Brief: BioMaxima Signs 3.2 Mln Zlotys Deal With Polish Pharmaceutical Company
Brief: Biomaxima Feb Sales Revenue At 38.5 Mln Zlotys
Brief: Biomaxima Jan Sales Revenue At 43.7 Mln Zlotys
Poland - Factors to Watch Feb 1
Poland - Factors to Watch Jan 31
Brief: Biomaxima Gets 94.8 Mln Zloty Order For SARS-CoV-2 Tests
Brief: Biomaxima Says Prelim Q4 Revenue At 23.2 Mln Zlotys
Brief: Biomaxima Signs 8.9 Mln Zloty Deal For Rapid Antigene SARS-CoV-2 Tests
Brief: Biomaxima Prelim Q3 Standalone Sales Revenue At 14.4 Mln Zlotys, Up 101.58% Y/Y
Brief: Biomaxima Says Files To KNF For Listing On Regulated Market
Brief: BioMaxima Q1 Net Result Turns To Profit Of 6.4 Mln Zlotys
Brief: Biomaxima Prelim Q1 Standalone Sales Revenue At 26.4 Mln Zlotys
Polish BioMaxima eyes takeovers after its value surged on pandemic
Brief: Biomaxima Signs Deal With Germany-Based Distributor On Products Related To Sars-Cov-2 Diagnostics